Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | PHGDH | O43175 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 5/20 | 0.40 |
| ▸ | HTR7 | P34969 | 3/20 | 0.40 |
| ▸ | HTR1A | P08908 | 2/20 | 0.40 |
| ▸ | HTR2A | P28223 | 2/20 | 0.40 |
| ▸ | DRD3 | P35462 | 2/20 | 0.40 |
| ▸ | HTR6 | P50406 | 2/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.40 |
| ▸ | PMM2 | O15305 | 1/20 | 0.38 |
| ▸ | MPI | P34949 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1540146 | 0.79 | ALDH1A1 (0.55) | FFAR4MAPTSMN1; SMN2HTTRAB9A | |
| SCHEMBL6239706 | 0.77 | FFAR4 (0.49) | FFAR4MAPTSMN1; SMN2HTTRAB9A | |
| SCHEMBL1111778 | 0.76 | PHGDH (0.48) | FFAR4MAPTSMN1; SMN2HTTRAB9A | |
| SCHEMBL27613691 | 0.76 | PRMT6 (0.50) | FFAR4MAPTSMN1; SMN2HTTRAB9A | |
| Hydrochloric Acid SCHEMBL27858925 | 0.74 | PRMT6 (0.49) | FFAR4MAPTSMN1; SMN2HTTRAB9A | |
| SCHEMBL1678428 | 0.73 | ADRB1 (0.62) | MAPTHTTALDH1A1HTR2CHTR7 | |
| SCHEMBL1111661 | 0.73 | ADRB1 (0.62) | MAPTHTTALDH1A1HTR2CHTR7 | |
| SCHEMBL518966 | 0.72 | MAPT (0.57) | MAPTSMN1; SMN2HTTRAB9AALDH1A1 | |
| Hydrochloric Acid SCHEMBL30609613 | 0.72 | ADRB1 (0.60) | MAPTHTTALDH1A1HTR2CHTR7 | |
| SCHEMBL1039993 | 0.71 | ALDH1A1 (0.48) | MAPTSMN1; SMN2RAB9AALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3048098-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | AbbVie Bahamas Limited (BS) | 2016-07-27 | — | — | EP | disclosed |
| EP-1685119-B1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBVIE BAHAMAS LTD (BS) | 2016-03-09 | — | — | EP | disclosed |
| US-9045444-B2 | Apoptosis promoters | ABBVIE INC. (US) | 2015-06-02 | — | — | US | disclosed |
| US-20140187531-A1 | APOPTOSIS PROMOTERS | ABBVIE INC. (US) | 2014-07-03 | — | — | US | disclosed |
| EP-2308812-B1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBVIE BAHAMAS LTD (BS) | 2014-02-26 | — | — | EP | disclosed |
| US-8614318-B2 | Apoptosis promoters | ABBVIE INC. (US) | 2013-12-24 | — | — | US | disclosed |
| US-20130190488-A1 | APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2013-07-25 | — | — | US | disclosed |
| US-8354404-B2 | Apoptosis promoters | ABBOTT LABORATORIES (US) | 2013-01-15 | — | — | US | disclosed |
| US-8173811-B2 | Apoptosis promoters | ABBOTT LABORATORIES (US) | 2012-05-08 | — | — | US | disclosed |
| US-8084607-B2 | Apoptosis promoters | ABBOTT LABORATORIES (US) | 2011-12-27 | — | — | US | disclosed |
| US-20100022773-A1 | APOPTOSIS PROMOTERS | ABBVIE INC. | 2010-01-28 | — | — | US | disclosed |
| US-7642260-B2 | N-acylsulfonamide derivatives; BCL-X1 protein inhibitors; anticarcinogenic agents; bladder cancer; for example, N-(4-(4-((4'-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)-propyl)amino)-3-nitrobenzenesulfonamide | ABBOTT LABORATORIES, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| US-20070072860-A1 | N-acylsulfonamide derivatives; BCL-X1 protein inhibitors; anticarcinogenic agents; bladder cancer; for example, N-(4-(4-((4'-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)-propyl)amino)-3-nitrobenzenesulfonamide | ABBOTT LABORATORIES | 2007-03-29 | — | — | US | disclosed |
| US-20070015787-A1 | Apoptosis promoters | ABBVIE INC. | 2007-01-18 | — | — | US | disclosed |
| US-20060258657-A1 | Apoptosis promoters | ABBVIE INC. | 2006-11-16 | — | — | US | disclosed |
| EP-1685119-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | Abbott Laboratories (US) | 2006-08-02 | — | — | EP | disclosed |
| US-20060128706-A1 | Apoptosis promoters | ABBVIE INC. | 2006-06-15 | — | — | US | disclosed |
| US-20050159427-A1 | N-acylsulfonamide apoptosis promoters | ABBOTT LABORATORIES | 2005-07-21 | — | — | US | disclosed |
| WO-2005049593-A2 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2005-06-02 | — | — | WO | disclosed |
| WO-2005049594-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2005-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128706-A1 | Apoptosis promoters | BAX, BCL2, API5 | FFAR4 4495/4885MAPT 4100/4885SMN1; SMN2 2412/4885 |
| US-20130190488-A1 | APOPTOSIS PROMOTERS | BAX, BCL2, API5 | FFAR4 4495/4885MAPT 4100/4885SMN1; SMN2 2412/4885 |
| US-20070015787-A1 | Apoptosis promoters | BAX, BCL2, API5 | FFAR4 4495/4885MAPT 4100/4885SMN1; SMN2 2412/4885 |
| US-20060258657-A1 | Apoptosis promoters | BAX, BCL2, API5 | FFAR4 4495/4885MAPT 4100/4885SMN1; SMN2 2412/4885 |
| US-20100022773-A1 | APOPTOSIS PROMOTERS | BAX, BCL2, API5 | FFAR4 4495/4885MAPT 4100/4885SMN1; SMN2 2412/4885 |
| US-20050159427-A1 | N-acylsulfonamide apoptosis promoters | BAX, API5, CCAR2 | FFAR4 3711/4885MAPT 4640/4885SMN1; SMN2 1110/4885 |
| US-20140187531-A1 | APOPTOSIS PROMOTERS | BAX, BCL2, API5 | FFAR4 4495/4885MAPT 4100/4885SMN1; SMN2 2412/4885 |
| US-20070072860-A1 | N-acylsulfonamide derivatives; BCL-X1 protein inhibitors; anticarcinogenic agents; bladder cancer; for example, N-(4-(4-((4'-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)-propyl)amino)-3-nitrobenzenesulfonamide | BCL2A1, BAX, BCL2L1 | FFAR4 3630/4885MAPT 4463/4885SMN1; SMN2 2635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.